NCT02342067View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

April 30, 2015

Conditions
Healthy
Interventions
DRUG

Cenicriviroc

CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40

DRUG

Pioglitazone

PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40

Trial Locations (1)

80228

DaVita Clinical Research, Lakewood

All Listed Sponsors
lead

Tobira Therapeutics, Inc.

INDUSTRY

NCT02342067 - Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination | Biotech Hunter | Biotech Hunter